Important Message: COVID-19
We are now home-based during the COVID-19 pandemic but available and working. Responses may however take longer than normal as staff may be working altered hours but we are cross covering trials as required and urgent matters will be dealt with promptly. Please do not contact our usual office/landline number and instead email the trial contact and copy in the trial mailbox (firstname.lastname@example.org). If a query requires a prompt response please mark as ‘urgent’ in the email subject header.
RePHILL (Resuscitation with Pre-Hospital Blood Products) is a multi-centre randomised controlled trial of pre-hospital blood product administration versus standard care for traumatic haemorrhage, funded by the National Institute for Health Research (NIHR) Efficacy & Mechanism Evaluation Programme (EME; project number 14/152/14). The trial will test the hypothesis that Pre-Hospital Blood Products (PHBP) resuscitation with up to two units each of packed red blood cells (PRBC) and lyophilised plasma (LyoPlas N-w) will improve tissue perfusion (as measured by lactate clearance) and reduce mortality in trauma patients with haemorrhagic shock compared to the current standard practice of crystalloid (normal saline) resuscitation.
RePHILL included an internal pilot phase, where the trial opened in the West Midlands. The trial then rolled out to and the East Midlands and East Anglia.
The air ambulance services currently involved in the RePHILL trial are: Midlands Air Ambulance (MAA), The Air Ambulance Service (TAAS), MAGPAS and East Anglian Air Ambulance (EAAA).These are supplied by the following blood banks: New Cross Hospital, University Hospitals Coventry and Warwickshire, Cambridge University Hospitals, Norfolk & Norwich University Hospital and Worcester Acute Hospital. RePHILL patients are then transferred to one of the following emergency departments: the Queen Elizabeth Hospital (Birmingham), Walsgrave Hospital (Coventry), Addenbrooke's Hospital (Cambridge), Norfolk and Norwich Hospital, Royal Stoke University Hospital, the Queen's Medical Centre (Nottingham), Luton and Dunstable Hospital, Southmead Hospital (Bristol), Oxford Radcliffe Hospital, Sheffield Teaching Hospital and the Royal London Hospital.
For a statement on our data protection policy, please see: www.birmingham.ac.uk/research/bctu/data-sharing-policy.aspx
A multi-centre randomised controlled trial of pre-hospital blood product administration versus standard care for traumatic haemorrhage.
The principle objective of this trial is to investigate the clinical effectiveness of Pre-Hospital Blood Products (PHBP) resuscitation compared to the current standard care of restricted crystalloid based resuscitation in participants suffering from major traumatic haemorrhage.
Pre Hospital Emergency Medicine (PHEM) and Major Trauma Centres (MTC)
Patients believed to be over the age of 16 who have sustained a traumatic injury resulting in haemorrhage.
Participants will be randomised between crystalloid resuscitation (up to four 250ml bags of 0.9% sodium chloride) or Pre-Hospital Blood Products resuscitation (up to two units of packed red blood cells and two units of LyoPlas).
The views expressed are those of the authors and not necessarily those of the NHS, NIHR or the Department of Health.